On 2014 Sep 26, Swapnil Hiremath commented:

This study was discussed on Sep 23rd 2014 in the open, online, nephrology journal club, #NephJC, on twitter. Introductory comments are available at the PBFluids blog and at the NephJC website. It was a scintillating discussion, with more than 20 participants and over 300 tweets. A transcript and a curated (i.e. Storified) version of the tweetchat are available from the NephJC website. It was also the subject of a write-up on MedPage today. The highlights of the tweetchat were:

· Most clinicians already use renin-angiotensin system blockade for treatment of diabetic nephropathy and this is necessary, but far from sufficient to stop the rising tide of diabetic patients starting dialysis.

· Pentoxifylline does represent an extremely promising and inexpensive agent for these patients, and the investigators should be commended for choosing the appropriate population to study, and following through with a well-designed and conducted trial.

· The next step that most participants would like to see is a large, multi-centre trial which will study clinical endpoints such as need for renal replacement therapy.

Lastly, there was universal, unmistakable and unanimous unhappiness with the current journal style of relegating the Methods after the discussion at the end of the article.

Interested individuals can track and join in the conversation by following @NephJC and #NephJC on twitter, or by visiting the webpage at NephJC.com.

On 2014 Sep 26, Swapnil Hiremath commented:

This study was discussed on Sep 23rd 2014 in the open, online, nephrology journal club, #NephJC, on twitter. Introductory comments are available at the PBFluids blog and at the NephJC website. It was a scintillating discussion, with more than 20 participants and over 300 tweets. A transcript and a curated (i.e. Storified) version of the tweetchat are available from the NephJC website. It was also the subject of a write-up on MedPage today. The highlights of the tweetchat were:

· Most clinicians already use renin-angiotensin system blockade for treatment of diabetic nephropathy and this is necessary, but far from sufficient to stop the rising tide of diabetic patients starting dialysis.

· Pentoxifylline does represent an extremely promising and inexpensive agent for these patients, and the investigators should be commended for choosing the appropriate population to study, and following through with a well-designed and conducted trial.

· The next step that most participants would like to see is a large, multi-centre trial which will study clinical endpoints such as need for renal replacement therapy.

Lastly, there was universal, unmistakable and unanimous unhappiness with the current journal style of relegating the Methods after the discussion at the end of the article.

Interested individuals can track and join in the conversation by following @NephJC and #NephJC on twitter, or by visiting the webpage at NephJC.com.